United States — Centers for Disease Control and Prevention & Mapp Biopharmaceutical

United States — Centers for Disease Control and Prevention: United States — Centers for Disease Control and Prevention is partnering with the World Health Organization and authorities in the Democratic Republic of the Congo and Uganda to design and implement clinical trials.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention>>> declared the Ebola outbreak a Public Health Emergency of Continental Security, emphasizing the urgency of coordinated action and mobilizing resources for response and preparedness.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.

United States — Centers for Disease Control and Prevention: Confirmed a U.S. citizen infected; providing technical assistance.

Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.